Evotec, a Germany-listed chemicals company, has agreed to buy Kinaxo Biotechnologies, a local drug discovery company backed by High-Tech Gründerfonds, a €272m ($370m) state-backed fund supported by industrial groups BASF, Deutsche Telekom, Siemens, Robert Bosch, Daimler and Carl Zeiss. Evotec is paying €3m in cash and 2.6 million of its shares (worth €3.09 each at…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.